The Experts below are selected from a list of 246 Experts worldwide ranked by ideXlab platform
Monici P Preti - One of the best experts on this subject based on the ideXlab platform.
-
treatment of dermatomycoses with topical Fenticonazole and econazole lokalbehandlung von dermatomykosen mit fenticonazol und econazol
Mycoses, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, Monici P PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of Fenticonazole 2% cream or to econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the Fenticonazole group and only 13 from the included in the econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of Fenticonazole action was more rapid then that of econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with Fenticonazole and in 10 patients out of the 24 treated with econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
E. M. Kokoschka - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Dermatomycoses with Topical Fenticonazole and Econazole/Lokalbehandlung von Dermatomykosen mit Fenticonazol und Econazol
Mykosen, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, P. Monici PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of Fenticonazole 2% cream or to econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the Fenticonazole group and only 13 from the included in the econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of Fenticonazole action was more rapid then that of econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with Fenticonazole and in 10 patients out of the 24 treated with econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
-
treatment of dermatomycoses with topical Fenticonazole and econazole lokalbehandlung von dermatomykosen mit fenticonazol und econazol
Mycoses, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, Monici P PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of Fenticonazole 2% cream or to econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the Fenticonazole group and only 13 from the included in the econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of Fenticonazole action was more rapid then that of econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with Fenticonazole and in 10 patients out of the 24 treated with econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
M. Mounari - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of Dermatomycoses with Topical Fenticonazole and Econazole/Lokalbehandlung von Dermatomykosen mit Fenticonazol und Econazol
Mykosen, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, P. Monici PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of Fenticonazole 2% cream or to econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the Fenticonazole group and only 13 from the included in the econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of Fenticonazole action was more rapid then that of econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with Fenticonazole and in 10 patients out of the 24 treated with econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
-
treatment of dermatomycoses with topical Fenticonazole and econazole lokalbehandlung von dermatomykosen mit fenticonazol und econazol
Mycoses, 2009Co-Authors: E. M. Kokoschka, G. Niebauer, M. Mounari, Monici P PretiAbstract:Summary: Fifty-two patients suffering from dermatomycoses were randomly assigned either to a treatment of Fenticonazole 2% cream or to econazole 1% cream in an double blind trial. Patients were evaluated clinically, microscopically and by culture before entering the study and then at weekly intervals for 4 weeks. The creams were applied twice daily. 24 patients out of the 28 included in the Fenticonazole group and only 13 from the included in the econazole group were definitively cured or presented marked improvement (difference statistically significant, p < 0,02). The onset of Fenticonazole action was more rapid then that of econazole. Complete recovery based on the disappearance of direct microscopic evidence and on clinical healing was noted in 15 patients out of the 28 treated with Fenticonazole and in 10 patients out of the 24 treated with econazole. No side effects were observed in either group. Zusammenfassung: 52 Patienten mit Dermatomykosen wurden in einer Doppelblindstudie mit entweder 2% Fenticonazol-Creme oder 1% Econazol-Creme behandelt. Die Patienten wurden klinisch und mykologisch vor der Studie und in wochentlichen Abstanden uber vier Wochen untersucht. Die Creme wurde 2mal taglich angewendet. 24 von 28 mit Fenticonazol behandelten und 13 von 24 mit Econazol behandelten Patienten wurden vollstandig geheilt oder zeigten deutliche Besserung (statistische Signifikanz p < 0,02). Die Wirkung trat bei Fenticonazol fruher als bei Econazol ein. Nebenwirkungen wurden in keiner der beiden Gruppen beobachtet.
-
A double blind evaluation of Fenticonazole cream 2% and clotrimazole cream 1% in dermatomycoses.
Mykosen, 2009Co-Authors: A. Finzi, P. Monici Preti, A. Fioroni, M. MounariAbstract:Summary: 21 patients suffering from dermatomycoses were randomly assigned either to 2% Fenticonazole cream or 1% clotrimazole cream. The study was performed under double-blind conditions and on patients, with symmetrical or clinically comparable lesions. Patients were evaluated, clinically, microscopically and by culture before entering the study and then at weekly intervals for four weeks. The cream was applied twice daily. Eighteen lesions from the 21 treated with Fenticonazole 2% cream and 13 lesions out of 21 treated with clotrimazole 1% cream were definitely cured. The differences between the two treatments were statistically significant in favour of Fenticonazole in the third week of treatment (p < 0.05 - chi square test). Zusammenfassung: 21 Patienten mit Dermatomykosen, die symmetrisch lokalisiert und klinisch vergleichbar waren, wurden in einer Doppelblindstudie seitenvergleichend mit 2% Fenticonazol-Creme und 1% Clotrimazol-Creme behandelt. Klinische, mikroskopische und kulturelle Untersuchungen wurden vor Beginn der Behandlung und dann in wochentlichen Intervallen uber 4 Wochen durchgefuhrt. Die Creme wurde zweimal taglich aufgetragen. Bei 18 von 21 mit Fenticonazol 2%-Creme behandelten Falle und bei 13 von 21 mit Clotrimazol 1%-Creme behandelten wurde vollstandige Abheilung erreicht. In der dritten Behandlungswoche envies sich das gunstigere Behandlungsergebnis mit Fenticonazol als statistisch signifikant (p < 0,05 — chi Quadrattest).
Emiliano Panconesi - One of the best experts on this subject based on the ideXlab platform.
-
New therapeutic approach in skin mycoses: a comparative trial once versus twice daily application of Fenticonazole in comparison to miconazole
Mycoses, 2009Co-Authors: P. Vannini, Elisa Margherita Difonzo, C. I. Cordaro, A. Sartani, Emiliano PanconesiAbstract:Summary: Fenticonazole is a new potent anti-mycotic agent Its efficacy and tolerability in once and twice daily applications were compared in a double-blind trial with those of miconazole, in the treatment of superficial skin mycoses, in 60 patients randomly assigned to the 3 treatment groups. A comparison of the mycological and clinical cure rates of these well-matched groups showed no difference between treatments. It is concluded that Fenticonazole is a useful treatment for cutaneous fungal infections and when applied once daily it has clear advantages due to improved patient's compliance. Zusammenfassung: Fenticonazol ist ein neues potentes Antimykotikum. In einer Doppel-blindstudie wurden Wirksamkeit und Vertraglichkeit einer taglichen Einmal- und Zweimal- anwendung von Fenticonazol mit der von Miconazol bei der Behandlung von Hautmykosen an 60 randomisierten Patienten in drei Behandlungsgruppen verglichen. In der mykologischen und klinischen Heilungsrate zeigten sich in den drei Behandlungsgruppen keine Unterschiede. Daraus wird geschlossen, das Fenticonazol ein wirksames Mittel gegen Hautmykosen darstellt und das die tagliche Einmalanwendung wegen der verbesserten Patienten-Compliance klare Vorteile hat.
L. De Cecco - One of the best experts on this subject based on the ideXlab platform.
-
Evaluation of the efficacy and tolerability of two different dosages of Fenticonazole vaginal ovules (600 mg and 1000 mg) in patients with vaginal trichomoniasis : a controlled, double-blind randomized clinical trial versus placebo
Current Therapeutic Research-clinical and Experimental, 1994Co-Authors: Franco Gorlero, S. Macchiavello, L. Pellegatta, M.l. Airoldi, B. Gaffuri, L. Pulici, L. De CeccoAbstract:Abstract A double-blind clinical trial was performed in two clinical centers to evaluate the efficacy and the safety of two dose schedules of Fenticonazole (one 600-mg or one 1000-mg ovule applied for 2 consecutive days) versus placebo in the treatment of vaginal trichomoniasis. Sixty-one patients were included in the study in the following three treatment groups: 600-mg ovules, 21 patients; 1000-mg ovules, 20 patients; and placebo, 20 patients. A vaginal swab was obtained before treatment and on day 7 for phase-contrast direct microscopic identification of Trichomonas species and a cultural examination was performed to exclude a possible mycotic or bacterial etiology. The severity of vaginal signs and symptoms (erythema, itching, discharge, edema, and burning) were evaluated with a semiquantitative scale (0 to 3). At baseline, all patients were positive for Trichomonas vaginalis on microscopic examination; on final evaluation the test was negative in 13 (65.0%) patients in the 600-mg group (one patient did not have a final examination performed), in 10 (58.8%) of the 1000-mg group, and in 3 (15.0%) of the placebo group. The difference between patients receiving active drug and placebo was highly significant (chi-square test, P ≤ 0.005), while no significant difference existed between the two groups of drug-treated patients. A highly significant reduction of the symptomatic scores was observed in both active-treatment groups as compared with placebo, but, as in the case of the microbiologic findings, no difference was found between the two groups of Fenticonazole-treated patients. Side effects of mild or moderate intensity were present in three patients in the 1000-mg dose group. Two patients had a burning sensation and one had a burning sensation and discharge. One of the patients with a burning sensation interrupted the treatment. Such symptoms could also be part of the underlying disease.